At the end of the latest market close, Evofem Biosciences Inc. (EVFM) was valued at $2.07. In that particular session, Stock kicked-off at the price of $2.09 while reaching the peak value of $2.11 and lowest value recorded on the day was $2.05. The stock current value is $2.06.
Recently in News on December 17, 2020, Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea. High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Evofem Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.21 on 02/19/20, with the lowest value was $1.91 for the same time period, recorded on 09/24/20.
Evofem Biosciences Inc. (EVFM) full year performance was -64.12%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Evofem Biosciences Inc. shares are logging -71.50% during the 52-week period from high price, and 7.59% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.91 and $7.21.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 754930 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Evofem Biosciences Inc. (EVFM) recorded performance in the market was -66.45%, having the revenues showcasing -12.29% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 168.29M, as it employees total of 53 workers.
Analysts verdict on Evofem Biosciences Inc. (EVFM)
During the last month, 0 analysts gave the Evofem Biosciences Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.61, with a change in the price was noted -0.83. In a similar fashion, Evofem Biosciences Inc. posted a movement of -28.55% for the period of last 100 days, recording 3,685,907 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for EVFM is recording 1.20 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Evofem Biosciences Inc. (EVFM): Technical Analysis
Raw Stochastic average of Evofem Biosciences Inc. in the period of last 50 days is set at 3.68%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.95%. In the last 20 days, the company’s Stochastic %K was 5.09% and its Stochastic %D was recorded 6.59%.
Let’s take a glance in the erstwhile performances of Evofem Biosciences Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -66.45%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -29.35%, alongside a downfall of -64.12% for the period of the last 12 months. The shares increased approximately by -4.17% in the 7-day charts and went up by -5.91% in the period of the last 30 days. Common stock shares were lifted by -12.29% during last recorded quarter.